Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4787711
Max Phase: Preclinical
Molecular Formula: C26H36N4O5
Molecular Weight: 484.60
Molecule Type: Unknown
Associated Items:
ID: ALA4787711
Max Phase: Preclinical
Molecular Formula: C26H36N4O5
Molecular Weight: 484.60
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCOCC(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)(C)C)NC(=O)c1cc2ccccc2[nH]1
Standard InChI: InChI=1S/C26H36N4O5/c1-5-35-15-22(31)19(13-17-10-11-27-23(17)32)29-25(34)21(14-26(2,3)4)30-24(33)20-12-16-8-6-7-9-18(16)28-20/h6-9,12,17,19,21,28H,5,10-11,13-15H2,1-4H3,(H,27,32)(H,29,34)(H,30,33)/t17-,19-,21-/m0/s1
Standard InChI Key: KSTGVGSBRODERS-CUWPLCDZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 484.60 | Molecular Weight (Monoisotopic): 484.2686 | AlogP: 2.32 | #Rotatable Bonds: 11 |
Polar Surface Area: 129.39 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.77 | CX Basic pKa: | CX LogP: 1.78 | CX LogD: 1.78 |
Aromatic Rings: 2 | Heavy Atoms: 35 | QED Weighted: 0.39 | Np Likeness Score: -0.16 |
1. Hoffman RL,Kania RS,Brothers MA,Davies JF,Ferre RA,Gajiwala KS,He M,Hogan RJ,Kozminski K,Li LY,Lockner JW,Lou J,Marra MT,Mitchell LJ,Murray BW,Nieman JA,Noell S,Planken SP,Rowe T,Ryan K,Smith GJ,Solowiej JE,Steppan CM,Taggart B. (2020) Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19., 63 (21): [PMID:33054210] [10.1021/acs.jmedchem.0c01063] |
Source(1):